These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 1974508)

  • 21. Safety of the coadministration of carvedilol and nifedipine sustained-release in the treatment of essential hypertension.
    Juttmann JR; de Vries Robles P; Venuti RP
    J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S134-7. PubMed ID: 1378141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of carvedilol on blood pressure in patients with mild to moderate hypertension. A dose response study.
    McPhillips JJ; Schwemer GT; Scott DI; Zinny M; Patterson D
    Drugs; 1988; 36 Suppl 6():82-91. PubMed ID: 2908306
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Carvedilol prevents severe hypertensive cardiomyopathy and remodeling.
    Barone FC; Campbell WG; Nelson AH; Feuerstein GZ
    J Hypertens; 1998 Jun; 16(6):871-84. PubMed ID: 9663928
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Value of carvedilol in congestive heart failure secondary to coronary artery disease.
    Das Gupta P; Broadhurst P; Raftery EB; Lahiri A
    Am J Cardiol; 1990 Nov; 66(15):1118-23. PubMed ID: 1977300
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN).
    Komajda M; Lutiger B; Madeira H; Thygesen K; Bobbio M; Hildebrandt P; Jaarsma W; Riegger G; Rydén L; Scherhag A; Soler-Soler J; Remme WJ;
    Eur J Heart Fail; 2004 Jun; 6(4):467-75. PubMed ID: 15182773
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypotension with dobutamine: beta-adrenergic antagonist selectivity at low doses of carvedilol.
    Lindenfeld J; Lowes BD; Bristow MR
    Ann Pharmacother; 1999 Dec; 33(12):1266-9. PubMed ID: 10630826
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Controlled-release carvedilol in the treatment of essential hypertension.
    Weber MA; Sica DA; Tarka EA; Iyengar M; Fleck R; Bakris GL
    Am J Cardiol; 2006 Oct; 98(7A):32L-38L. PubMed ID: 17023230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Usefulness of carvedilol in unstable angina pectoris.
    Brunner M; Faber TS; Greve B; Keck A; Schnabel P; Jeron A; Meinertz T; Just H; Zehender M
    Am J Cardiol; 2000 May; 85(10):1173-8. PubMed ID: 10801996
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Different patterns of peripheral versus central blood pressure in hypertensive patients treated with β-blockers either with or without vasodilator properties or with angiotensin receptor blockers.
    Polónia J; Barbosa L; Silva JA; Bertoquini S
    Blood Press Monit; 2010 Oct; 15(5):235-9. PubMed ID: 20577082
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of carvedilol in hypertension: an update.
    Leonetti G; Egan CG
    Vasc Health Risk Manag; 2012; 8():307-22. PubMed ID: 22661898
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonselective beta-adrenergic blockade with carvedilol does not hinder the benefits of exercise training in patients with congestive heart failure.
    Demopoulos L; Yeh M; Gentilucci M; Testa M; Bijou R; Katz SD; Mancini D; Jones M; LeJemtel TH
    Circulation; 1997 Apr; 95(7):1764-7. PubMed ID: 9107160
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of carvedilol on renal function.
    Dupont AG
    Eur J Clin Pharmacol; 1990; 38 Suppl 2():S96-100. PubMed ID: 1974513
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Carvedilol for systemic hypertension.
    Heber ME; Brigden GS; Caruana MP; Lahiri A; Raftery EB
    Am J Cardiol; 1987 Feb; 59(5):400-5. PubMed ID: 2880498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of acebutolol with and without hydrochlorothiazide versus carvedilol with and without hydrochlorothiazide in black patients with mild to moderate systemic hypertension.
    Radevski IV; Valtchanova SP; Candy GP; Tshele EF; Sareli P
    Am J Cardiol; 1999 Jul; 84(1):70-5. PubMed ID: 10404854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Results of therapy with carvedilol, a beta-blocker vasodilator with antioxidant properties, in hypertensive patients.
    Moser M; Frishman W
    Am J Hypertens; 1998 Jan; 11(1 Pt 2):15S-22S. PubMed ID: 9503102
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antianginal efficacy of carvedilol, a beta-blocking drug with vasodilating activity.
    Rodrigues EA; Lahiri A; Hughes LO; Kohli RS; Whittington JR; Raftery EB
    Am J Cardiol; 1986 Nov; 58(10):916-21. PubMed ID: 2877564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Response rate with respect to the blood pressure-lowering effect of the vasodilating and beta-blocking agent carvedilol.
    Rittinghausen R
    Drugs; 1988; 36 Suppl 6():92-101. PubMed ID: 2908307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of the alpha-/beta-blocking agent carvedilol on hepatic and systemic hemodynamics in patients with cirrhosis and portal hypertension.
    Sekiyama T; Komeichi H; Nagano T; Ohsuga M; Terada H; Katsuta Y; Satomura K; Aramaki T
    Arzneimittelforschung; 1997 Apr; 47(4):353-5. PubMed ID: 9150854
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.
    Bristow MR; Gilbert EM; Abraham WT; Adams KF; Fowler MB; Hershberger RE; Kubo SH; Narahara KA; Ingersoll H; Krueger S; Young S; Shusterman N
    Circulation; 1996 Dec; 94(11):2807-16. PubMed ID: 8941106
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Carvedilol versus verapamil in chronic stable angina: a multicentre trial.
    Hauf-Zachariou U; Blackwood RA; Gunawardena KA; O'Donnell JG; Garnham S; Pfarr E
    Eur J Clin Pharmacol; 1997; 52(2):95-100. PubMed ID: 9174677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.